AxoGen
AXGN
36.04
-0.27
-0.74%
AxoGen
US · AXGN
#2714 by market cap
Listed 1970
36.04
-0.27
-0.74%
Live - 5344 symbols - heartbeat 50s ago
· 2026-10-08 05:20
Pre-market
36.02
-0.06%
After-hours
36.04
0.00%
- Market cap
- 2.11B
- P/E (TTM)i
- -53.79
- P/Bi
- 8.25
- EPSi
- -0.34
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on AXGN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 13.15, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +20.21% YoY
Margins
- Gross margin
- 74.31%
- Operating margin
- -3.49%
- Net margin
- -6.97%
Key ratios & quality
- Enterprise valuei
- 2.12B
- Altman Z-Scorei
- 13.15
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 83.94M | 106.71M | 112.30M | 127.36M | 138.58M | 159.01M | 187.34M | 225.21M |
| Gross profit | 71.01M | 89.36M | 90.72M | 104.43M | 108.81M | 121.87M | 141.98M | 167.35M |
| Selling & admin expenses | 79.74M | 103.26M | 96.06M | 105.67M | 112.89M | 115.99M | 117.50M | 142.32M |
| Research & development | 11.77M | 17.51M | 17.85M | 24.18M | 25.63M | 27.34M | 27.77M | 32.89M |
| Operating profit | -20.50M | -31.41M | -23.18M | -25.42M | -29.71M | -21.46M | -3.29M | -7.85M |
| Pretax profit | -22.40M | -29.14M | -23.79M | -26.99M | -28.95M | -21.72M | -9.96M | -15.70M |
| Tax | -- | -- | -- | -- | -- | -- | -- | -- |
| Net profit | -22.40M | -29.14M | -23.79M | -26.99M | -28.95M | -21.72M | -9.96M | -15.70M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 | 0 | 0 |
| Diluted EPS | -0.60 | -0.74 | -0.60 | -0.65 | -0.69 | -0.51 | -0.23 | -0.34 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 48.56M | 56.66M | 60.08M | 59.90M | 61.46M | 69.73M |
| Gross profit | 34.93M | 42.02M | 45.99M | 44.41M | 46.19M | 50.67M |
| Selling & admin expenses | 30.50M | 33.49M | 36.52M | 41.81M | 41.50M | 44.24M |
| Research & development | 6.09M | 6.85M | 7.57M | 12.38M | 7.52M | 8.59M |
| Operating profit | -1.66M | 1.67M | 1.91M | -9.77M | -2.83M | -2.16M |
| Pretax profit | -3.83M | 579.00K | 708.00K | -13.16M | -19.58M | -1.52M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -3.83M | 579.00K | 708.00K | -13.16M | -19.58M | -1.52M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.08 | 0.01 | 0.01 | -0.28 | -0.38 | -0.03 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 150.95M | 135.02M | 145.25M | 127.05M | 98.08M | 88.00M | 99.22M | 120.42M |
| Cash & ST investments | 116.61M | 96.51M | 103.97M | 84.09M | 48.79M | 31.02M | 33.48M | 41.53M |
| Inventory | 11.98M | 13.86M | 12.53M | 16.69M | 18.91M | 23.02M | 33.18M | 42.37M |
| Total assets | 160.17M | 154.64M | 201.38M | 208.02M | 195.39M | 196.83M | 203.73M | 221.69M |
| Total current liabilities | 13.04M | 20.88M | 22.83M | 24.29M | 23.75M | 30.43M | 30.61M | 23.56M |
| Short-term debt | 28.00K | 1.74M | 863.00K | 1.83M | 1.31M | 1.55M | 1.97M | 2.37M |
| Long-term debt | 35.00K | -- | 32.03M | 44.82M | 45.71M | 46.60M | 47.50M | 48.39M |
| Total liabilities | 13,191,000.00 | 22,490,000.00 | 78,232,000.00 | 95,474,000.00 | 94,388,000.00 | 101,162,000.00 | 99,821,000.00 | 92,840,000.00 |
| Total equity | 146.98M | 132.15M | 123.15M | 112.55M | 101.00M | 95.67M | 103.91M | 128.85M |
| Retained earnings | -150.73M | -179.86M | -203.65M | -230.63M | -259.58M | -281.30M | -291.26M | -306.96M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 93.07M | 103.42M | 114.46M | 120.42M | 184.71M | 200.38M |
| Cash & ST investments | 22.07M | 29.92M | 35.79M | 41.53M | 101.60M | 111.41M |
| Inventory | 35.50M | 36.77M | 40.58M | 42.37M | 46.07M | 47.31M |
| Total assets | 196.17M | 205.45M | 216.40M | 221.69M | 289.49M | 304.86M |
| Total current liabilities | 21.75M | 24.98M | 28.01M | 23.56M | 26.01M | 30.37M |
| Short-term debt | 2.09M | 2.21M | 2.34M | 2.37M | 2.12M | 1.98M |
| Long-term debt | 47.72M | 47.94M | 48.16M | 48.39M | -- | -- |
| Total liabilities | 90,800,000.00 | 93,177,000.00 | 95,595,000.00 | 92,840,000.00 | 44,680,000.00 | 48,606,000.00 |
| Total equity | 105.37M | 112.28M | 120.81M | 128.85M | 244.81M | 256.26M |
| Retained earnings | -295.09M | -294.52M | -293.81M | -306.96M | -326.55M | -328.06M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -17.86M | -19.87M | -9.63M | -13.41M | -16.07M | -5.72M | 4.54M | 812.00K |
| Depreciation & amortization | 851.00K | 2.88M | 3.46M | 4.74M | 4.85M | 5.55M | 7.84M | 8.51M |
| Free cash flow | -24.47M | -25.10M | -32.22M | -41.81M | -37.32M | -20.63M | 11.00K | -4.78M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 132.96M | 0 | 3.50M | -- | -- | -- | -- | -- |
| Ending cash balance | 30.29M | 41.72M | 55.61M | 39.01M | 21.54M | 37.03M | 33.55M | 39.55M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -13.18M | 7.73M | 3.22M | 3.04M | 1.57M | 7.22M |
| Depreciation & amortization | 1.88M | 1.82M | 1.84M | 2.97M | 2.13M | 2.15M |
| Free cash flow | -13.84M | 6.62M | 1.36M | 1.08M | -1.40M | 5.47M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 134.04M | 0 |
| Ending cash balance | 24.10M | 26.04M | 27.90M | 39.55M | 84.65M | 96.57M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -26.02 | -20.88 | -18.63 | -22.90 | -27.11 | -22.08 | -9.99 | -13.49 |
| ROA %i | -20.45 | -18.51 | -13.36 | -13.18 | -14.35 | -11.07 | -4.98 | -7.38 |
| ROIC %i | -21.53 | -20.60 | -14.55 | -14.36 | -16.26 | -11.33 | -1.04 | -4.34 |
| 5-year avg ROE %i | -- | -- | -48.46 | -28.10 | -23.11 | -22.32 | -20.14 | -19.11 |
| EBIT margin %i | -25.24 | -27.27 | -20.24 | -20.12 | -20.44 | -11.87 | -0.94 | -3.55 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 0.01 | -- |
| Current ratioi | 11.57 | 6.47 | 6.36 | 5.23 | 4.13 | 2.89 | 3.24 | 5.11 |
| Quick ratioi | 10.11 | 5.43 | 5.33 | 4.21 | 2.99 | 1.85 | 1.88 | 2.87 |
| Debt / assetsi | 0.04 | 2.15 | 26.70 | 32.43 | 34.51 | 35.20 | 33.71 | 30.51 |
| LT debt / equityi | 0.02 | 1.21 | 42.96 | 58.30 | 65.46 | 70.81 | 64.21 | 50.65 |
| Interest coveragei | -17.54 | -727.38 | -21.57 | -18.90 | -45.39 | -6.66 | -0.21 | -1.04 |
| Revenue CAGR (3Y) %i | 45.36 | 37.43 | 22.95 | 14.91 | 9.10 | 12.29 | 13.73 | 17.57 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -7.22 | -4.48 | -1.90 | -13.49 | -17.96 | -18.21 |
| ROA %i | -3.74 | -2.36 | -1.03 | -7.38 | -12.95 | -13.15 |
| ROIC %i | 0.58 | 1.89 | 3.19 | -4.34 | -11.52 | -12.86 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 0.50 | 1.60 | 2.65 | -3.55 | -10.63 | -11.70 |
| FCF / sales %i | -- | 1.70 | 0.96 | -- | 3.22 | 2.59 |
| Current ratioi | 4.28 | 4.14 | 4.09 | 5.11 | 7.10 | 6.60 |
| Quick ratioi | 2.22 | 2.32 | 2.38 | 2.87 | 4.99 | 4.79 |
| Debt / assetsi | 34.89 | 33.19 | 31.38 | 30.51 | 7.13 | 6.58 |
| LT debt / equityi | 62.98 | 58.76 | 54.28 | 50.65 | 7.57 | 7.06 |
| Interest coveragei | 0.12 | 0.41 | 0.73 | -1.04 | -4.12 | -7.05 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Peripheral nerve repair100.00%
Quote time 2026-10-08 05:20:31 · For reference only, not investment advice and not tailored to your situation.